Log in or Sign up for Free to view tailored content for your specialty!
Neurology News
Tovorafenib exhibits ‘encouraging’ activity in pediatric low-grade glioma
Tovorafenib monotherapy induced response among approximately two-thirds of patients with recurrent or progressive pediatric low-grade glioma, according to topline data released by the agent’s manufacturer.
Treatment with nusinersen improved motor function up to 5 years in infantile-onset SMA
Treatment with nusinersen led to continued and improved motor function up to 5 years after initial dose in infants with spinal muscular atrophy, according to a poster presented at the International Scientific Congress on Spinal Muscular Atrophy.
Log in or Sign up for Free to view tailored content for your specialty!
Eisai submits supplemental application to FDA for traditional approval of Leqembi
The manufacturer of Leqembi announced it has submitted a supplemental Biologics License Application to the FDA to support the conversion of its recent accelerated approval to a traditional approval.
Endovascular implantation of brain-computer interface successful alternative to surgery
Endovascular access to the sensorimotor cortex was shown to be a successful alternative for placing a brain-computer interface in or on the dura compared with open-brain surgery, researchers reported in JAMA Neurology.
Quantitative test to measure neurofilament light chain validated
Quanterix Corp. announced the validation of a laboratory developed test to quantitatively measure neurofilament light chain in serum as an aid in the evaluation of those who may have neurodegenerative conditions.
Amyloid burden similar among those with Alzheimer's disease, Down syndrome
Amyloid positron emission tomography scan changes were similar between individuals with autosomal dominant Alzheimer’s disease and those with Down syndrome, researchers reported in The Lancet Neurology.
FDA grants accelerated approval for Alzheimer's treatment
The FDA has granted accelerated approval for Leqembi for the treatment of Alzheimer’s disease, making it the second approved Alzheimer’s treatment, the agency announced in a press release.
FDA gives priority review to generalized myasthenia gravis treatment
The FDA has given priority review to a biologic license application from UCB for rozanolixizumab, a treatment for adults with generalized myasthenia gravis, the biopharmaceutical company announced in a press release.
Neurological effects of long COVID: It is ‘not only a respiratory disease’
As the world continues to grapple with effects of the COVID-19 pandemic, individuals around the globe are still dealing with symptoms of SARS-CoV-2 infection for months, even years, after their initial infection.
Athira Pharma provides 2023 outlook for Alzheimer's, Parkinson’s, ALS trials
Athira Pharma Inc. will proceed in 2023 with several clinical trials for treatments for Alzheimer’s disease, Parkinson’s disease and ALS, the biopharmaceutical company announced in a press release.
-
Headline News
Tea, red wine among foods tied to lower risk for dementia
October 01, 20242 min read -
Headline News
Generic version of injectable acromegaly treatment launches in US
October 01, 20241 min read -
Headline News
VIDEO: Are herbs and supplements safe for children to use?
September 30, 20241 min watch
-
Headline News
Tea, red wine among foods tied to lower risk for dementia
October 01, 20242 min read -
Headline News
Generic version of injectable acromegaly treatment launches in US
October 01, 20241 min read -
Headline News
VIDEO: Are herbs and supplements safe for children to use?
September 30, 20241 min watch